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Abstract 
Purpose: The recommended value for the relative biological effectiveness (RBE) of proton beams 
is currently assumed to be 1.1. However, there is increasing evidence that RBE increases towards 
the end of proton beam range that may increase the biological effect of proton beam in the distal 
regions of the dose deposition. Methods: A computational approach is presented for estimating the 
biological effect of the proton beam. It includes a method for calculating the dose averaged linear 
energy transfer (LET) along the measured Bragg peak and published LET to RBE conversion rou-
tine. To validate the proposed method, we have performed Monte Carlo simulations of the pristine 
Bragg peak at various beam energies and compared the analysis with the simulated results. A 
good agreement within 5% is observed between the LET analysis of the modeled Bragg peaks and 
Monte Carlo simulations. Results: Applying the method to the set of Bragg peaks measured at a 
proton therapy facility we have estimated LET and RBE values along each Bragg peak. Combining 
the individual RBE-weighted Bragg peaks with known energy modulation weights we have calcu-
lated the RBE-weighted dose in the modulated proton beam. The proposed computational method 
provides a tool for calculating dose averaged LET along the measured Bragg peak. Conclusions: 
Combined with a model to convert LET into RBE, this method enables calculation of RBE-weighted 
dose both in pristine Bragg peak and in modulated beam in proton therapy. 
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Proton beams offer clinically favorable dose distribution due to their unique energy deposition characteristics in 
the form of the Bragg peak and finite penetration depth with near-zero dose beyond a certain depth known as 
range. These unique features provide possibilities for dose escalations to improve radiation outcomes with sig-
nificant reduction in radiation related toxicities and complications [1]-[4]. The improved clinical outcome poten-
tials of proton beams have driven interest in radiation oncology community, with clearly visible growth in the 
number of proton therapy facilities worldwide. While physical properties of proton beams are well established, 
the biological effects are still an active area of research with large uncertainties [5] [6]. 
The majority of proton therapy facilities have adopted a constant value of 1.1 for the relative biological effec-
tiveness (RBE) of proton beams based on international recommendations [6] [7]. However there are ample evi-
dences that the RBE in particle beams is not constant rather depends on beam energy, location, dose fractiona-
tion and tissue type. Many experimental approaches in determining RBE of proton beam have been suggested 
depending upon the biological sample [8]-[15] as reflected in many publications that summarize the measured 
values [5] [6]. There is also a growing concern among clinicians who have observed adverse biological effect at 
the end of Bragg peak for brain and spinal cord irradiations [16]-[18]. 
The experimentally measured RBE dependence on linear energy transfer (LET) suggests that the RBE value 
increases towards the end of beam range (as the energy decreases) that could increase the biological effect of 
proton radiation in the distal regions of the dose deposition [15] [19] [20]. To quantify this effect, the product of 
the deposited (physical) dose and the RBE, referred to as RBE-weighted dose, can be used. Radiobiological ex-
periments [21] using monoenergetic proton beams have established general dependence of the RBE on the linear 
energy transfer (LET). Furthermore, phenomenological model [22] has been proposed linking the RBE effect 
with the proton dose per fraction, LET value, and tissue sensitivity to reference x-ray radiation expressed in α 
and β parameters of the linear-quadratic model [23]. The challenge remains to estimate the biological effect at 
the distal edge of the Bragg peak as the LET distributions can vary significantly depending on the hardware 
configuration and beam properties in the treatment nozzle [24]. In clinical practice, individual proton therapy 
nozzles are parameterized and calibrated by measuring depth dose distribution in water for a set of beam ener-
gies thus providing pristine Bragg peak measurements, which are specific to the proton beam-line design. These 
individual Bragg peaks can be combined with appropriate weighting factors to provide Spread Out Bragg Peak 
(SOBP) by selecting sequential beam energy reduction (or Bragg peak pull back), which would provide the re-
quired target coverage in depth. As variability of Bragg peak properties among treatment centers is well known 
[25], one can also expect variation in RBE measurements at different facilities. A possible link of RBE variabil-
ity with proton beam line design has been observed by Paganetti and Goitein [24]. 
The main focus of this paper is to develop a computational method for RBE based on dose averaged LET (see 
Equation (2)) values from a measured depth dose data for clinical beam. While for the same treatment range 
Bragg peak shape may differ between different treatment centers, we do expect that the method presented here is 
universally applicable for converting measured Bragg peaks into RBE-weighted Bragg peaks. Once the RBE 
values are calculated along individual Bragg peaks, one can generate RBE-weighted SOBP dose distributions 
for clinical usage. 
2. Materials and Methods 
Ionization track structures and microdosimetric energy spectra of protons at various depths are typically ana-
lyzed to convert LET [26]-[30] of individual protons into an RBE value [13] [31] [32], of a therapeutic beam. 
We propose a simple method that allows one to determine the dose averaged LET value at each point along the 
measured Bragg peak. Instead of integrating proton spectra with proton stopping power along each track, we 
take the ratio of the energy deposited per unit length to proton beam fluence (see Equation (2)) to define dose 
averaged LET. Assuming that the RBE-LET relationship is known, we can then calculate RBE values along the 
measured pristine Bragg peak to construct a “biological”, or RBE-weighted pristine Bragg peak. Applying the 
known pullbacks and respective energy modulation weights, one can determine the RBE-weighted dose in a 
modulated proton beam. 
2.1. LET Calculation Model 
The depth dose curve containing Bragg peak of the proton beam is divided into two regions: the proximal region 
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from the surface to the dose maximum and the distal region from the maximum to near zero dose. For every 
depth, point x measured from the material surface in the proximal region, we can define the residual range RRES 
as: 
80RESR R x= −                                           (1) 
where R80 is the proton beam penetration range measured at the distal 80% dose level of the Bragg peak. Using 
the published energy-range tables [33] we can convert the residual penetration range at a given point into either 
the effective proton energy or into the effective stopping power. The linear energy transfer is defined by the 
energy deposited in the target media per unit length. Its primary contribution comes from the beam energy losses 
per unit length or the beam stopping power. However, LET also includes an additional small contribution that 
comes from short range secondary particles created in nuclear interactions of the primary proton beam with the 
target media [34]. We assumed a small but constant correction factor for nuclear interactions, which adds to 
beam stopping power and allows defining a dose averaged LET for each point in depth proximal to the Bragg 
peak. The correction factor value for nuclear interactions is determined in Section 2.2 using Monte-Carlo calcu-
lations.  
It is important to note the small disagreement between various range-energy tables. For example, for the same 
energy of 250 MeV ICRU Report 49 [33] and Janni [35] predict proton ranges in water that differ by 3 mm. If 
we were to take water surface as our normalization point and assumed same energy proton beam at the entrance, 
then after passing the same slab of water the disagreement in the proton stopping power values from different 
range energy tables can exceed 10%near the Bragg peak. By introducing the residual range, we can set our nor- 
malization point at R80, which introduces very small discrepancy in initial beam energy at the water surface but 
brings the overall agreement of stopping power calculations from various range-energy tables to within 2% as 
illustrated in Figure 1. 
Next we defined a method of calculating LET in the distal region of Bragg peak. Our most general assump- 
tion about distal region is that the dose averaged LET should be a smooth function of depth. The continuous 
slowing down approximation (CSDA) does not work beyond the Bragg peak since residual range becomes neg-
ative. Furthermore, the proton beam cannot be considered monoenergetic on the distal edge of the Bragg peak. 
Instead, the beam energy spectrum changes when it reaches energies below 3 MeV (residual range of 0.1 mm) 
as illustrated in Figure 2. Besides obvious asymmetry in the beam energy spectrum, the range of energies cor- 
responds to a wide range of LET values. Therefore, common RBE calculation methods include spectral analysis 
of the beam at every given point and integration of the dose deposition function with LET spectra [36]. This  
 
 
Figure 1. Comparison of stopping power in different Range-Energy tables for water 
in log-log scale. The horizontal scale is reversed to emphasize the stopping power 
behavior along the Bragg peak.                                             




Figure 2. Energy spectra on distal edge of 162 MeV Bragg peak obtained 
from Monte-Carlo calculations. Individual spectra at R05, R20, R50, R80 and 
R_peak were scaled down by factors of 1, 2, 3, 4, and 5 respectively.         
 
LET spectral analysis works well in Monte Carlo but is not practical for analysis of clinically measured Bragg 
peaks. Looking for an alternative method, we have observed in our Monte Carlo simulations that the dose aver-
aged LET exhibits a nearly linear increase with depth beyond the Bragg peak. Therefore, as a first approxima-
tion we assume that the dose averaged LET increases linearly with depth beyond the Bragg peak position and 
the slope of LET growth is defined by LET slope at the maximum dose point on the Bragg peak. 
Furthermore, when the physical dose drops below 1% level the biological effect becomes important only at 
the theoretical level. When the physical dose is negligible, the RBE value becomes irrelevant from a clinical 
point of view. Therefore, beyond the distal 1% - 2% depth dose point we assume constant LET and RBE values. 
This prevents magnification of the experimental noise which could be present in the region beyond the Bragg 
peak. 
2.2. Validation of the LET Calculation Model 
To validate the proposed model for LET calculation we have carried out Monte Carlo simulation of the dose 
distribution along depth generated by 1 cm diameter source of mono-energetic proton shitting a water target. 
The Monte-Carlo calculations were carried out using MCNPx code [37]. Using a cylindrical detector mesh with 
0.5 mm spacing in depth and 12 cm in diameter both the energy deposited and proton fluence in each cell was 
calculated. Instead of integrating the stopping power over the energy spectrum of the proton beam, we calcu-
lated the dose averaged LET through simple division of the energy deposited in each cell dE [MeV/cm3] by the 
proton beam fluence Φ [1/cm2]: 







                                  (2) 
We have calculated the depth dose distribution and dose averaged LET for monoenergetic proton beams at 
three energies 116 MeV, 162 MeV and 201 MeV corresponding to the penetration range R80 in water of about 
10 cm, 18 cm and 26 cm, respectively. We applied the LET calculation model outlined above to the Bragg peaks 
simulated with MCNPx to validate the proposed model. Thus, we could compare the LET model calculations to 
the MCNPx simulation results based on identical Bragg peaks. The comparison was first done for the proximal 
regions and then for the distal regions of the Bragg peaks. 
2.3. LET to RBE Conversion 
The most straight forward way to obtain RBE is to use experimental data from radiobiological experiment for a 
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particular cell line. However, taking the data from published experiments [32] we would find that only a few 
data point lie in the clinically relevant for proton therapy LET range below 200 MeV/cm.  
A more generic phenomenological model proposed by Wilkens and Oelfke [22] describing RBE as a function 
of proton dose Dp, the LET, and the tissue specific parameters α and β from a linear-quadratic cell survival pa-
rameterization:  
( )
( )( )2 4
, , ,
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=                (3) 
where subscripts p and x refer to proton and x-ray linear quadratic parameters, respectively. Analyzing published 
radiobiological experimental data Wilkens and Oelfke [22] concluded that in the LET region below 200 
MeV/cm, which is most relevant for clinical applications, a linear dependence of αp on LET could be assumed, 
while βp is essentially independent of LET and equal to βx: 




α α β β = + ⋅ − = 
 ⋅
                   (4) 
Note that such parameterization results in αp = αx at the entrance region of 170 MeV proton beam where the 
LET = 5 MeV/cm. In other words, monoenergetic proton beam has RBE = 1 at the entrance region into the wa-
ter equivalent media. To estimate RBE variation in different tissues and for different dose fractionation regimes 
we have compiled a short table (Table 1) of alpha beta values for common treatment sites in proton therapy. We 
then studied how the selection of tissue or dose per fraction changes the RBE behavior in the range of LET val-
ues applicable for proton therapy. 
2.4. RBE-Weighted Dose Calculation 
Finally we computed the RBE-weighted dose along the Bragg peak as a product of measured physical dose at a 
given depth x, and RBE factor calculated using phenomenological model (Equation (3)) for LET value at the 
same point on Bragg peak assuming proton dose delivery with 2 Gy or 4 Gy per fraction. In these calculations 
we used head and neck tissue alpha beta parameters since it represents a typical treatment site in proton therapy. 
The case of 4 Gy per fraction was calculated to evaluate the effect of hypo-fractionation in proton therapy that 
has been observed in many publications [15] [38]. 
( ) ( ) ( )( ), 2  4RBED x D x RBE LET x Gy or Gy= ⋅                          (5) 
The physical depth dose measurements were taken with a Markus ion chamber in a water phantom while de-
livering pristine energy proton beams with field sizes exceeding 5 cm in diameter. The measured depth dose 
curves were smoothed with Gaussian algorithm imbedded into the water phantom data acquisition software to 
eliminate signal noise associated with beam intensity fluctuations. These measured Bragg peaks were part of the 
commissioning data set taken in uniform scanning nozzle as described Farr et al. [39]. 
For proton beams modulated in depth, we calculated the RBE-weighted dose by combining RBE-weighted 
dose from individual Bragg peaks scaled according to monitor unit weights of individual energy layers. 
 
Table 1. Radiosensitivity parameters for tissues representing common treatment sites in proton therapy.                  
Tissue Type αx (Gy−1) βx (Gy−2) αx/βx (Gy) Ref. Rad. Reference 
Chordoma 0.1 0.050 2.0 Co-60 [42] 
Prostate 0.15 0.048 3.1 Co-60 [15] [43] 
Lung 0.19 0.052 3.7 Co-60 [44] 
Head & Neck 0.25 0.025 10 Co-60 [15] [45] [46] 




3.1. Validation of LET Calculation Model 
To validate the proposed model for LET calculation we used Monte Carlo modeling to investigate the LET be-
havior around the proton Bragg peak. Figure 3 shows calculated LET values plotted against the residual range 
for three different energies of the incident proton beam 116 MeV, 162 MeV and 201 MeV.  
The Monte Carlo simulation data indicate that LET behavior is nearly identical in the proximal region of the 
Bragg peak regardless of the incident beam energy. This pattern also agrees qualitatively with the LET predic- 
tions from the water range-energy tables. However, the stopping power values computed from the water range- 
energy table are consistently lower by about 7% due to missing contribution from the short range secondary par-
ticles created in the nuclear interactions. Similar nuclear buildup of about 6% has been observed experimentally 
at the entrance region of the Bragg peak. 
Including the 7% correction into the model, we applied the LET calculation method to the set of Bragg peaks 
simulated with MCNPx [37]. Figure 4 shows comparison of the LET values along the 162 MeV Bragg peak 
calculated with the model and with Monte Carlo. Similar analysis was also carried out for proton beam energies 
of 116 MeV and 201 MeV. With the exception of distal tail region, where physical dose is less than 1% of the 
peak value, the model demonstrates good agreement with Monte Carlo simulations. The deviation between the 
model calculations and Monte Carlo does not exceed 4% in the proximal region of Bragg peak, while in the dis-
tal region of Bragg peak the LET values may differ by up to 8%. This can be attributed to simplified linear LET 
behavior, which the model assumes in the distal region.  
3.2. RBE-Weighted Dose Calculation 
With the method for calculating LET values along the measured Bragg peak, the next step is to calculate RBE 
based on LET values. We compared the RBE behavior in the range of LET values relevant in proton therapy for 
different tissues as shown in Figure 5(a). For the selected tissue types we found very small variation of RBE 
values within the LET range of interest. We also compared the RBE behavior for different dose per fraction. 
Negligible RBE variation with dose was observed for the LET values below 10 MeV/cm corresponding to 
proximal region of the Bragg peak. However, near the Bragg peak and in the distal region of the Bragg peak the  
 
 
Figure 3. LET behavior on the proximal side of the Bragg peak calculated 
(Equation (2)) for three different proton beam energies and predictions from 
water range-energy tables. For each energy the position of Bragg peak is 
indicated with a triangle.                                              




Figure 4. Comparison of the Monte Carlo simulated LET to the LET analysis applied to the simulated Bragg 






Figure 5. Proton beam RBE values calculated from Equation (3) are plotted as a function of LET: (a) For dif-
ferent tissues and same fractional dose of 2 Gy; and (b) For different fractional dose but same tissue type. Ar-
rows on the top scale indicate expected residual range of protons in water for a given LET value.             
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RBE variation with dose become substantial and exceeds 10% for the LET values above 40 MeV/cm as shown 
in Figure 5(b).  
Applying the proposed method to the set of experimentally measured Bragg peaks, we obtained the 
RBE-weighted absorbed dose as shown in Figure 6. Combining the RBE-weighted Bragg peaks we then esti-
mated the biological dose in modulated beams that requires only the knowledge of weights of the individual 
Bragg peaks comprising the SOBP. Figure 7 shows physical and RBE-weighted SOBPs for large, medium and 
shallow proton beam penetration ranges and for two dose fractionation scenarios of 2 Gy and 4 Gy per fraction. 
 
 
Figure 6. Physical and RBE-weighted dose distributions are plotted against depth in water for 
a 152 MeV pristine Bragg peak.                                                    
 
 
Figure 7. Comparison of the physical dose and RBE-weighted dose in modulated proton 
beams.                                                                        




Our LET calculation approach is based on the observation that for nearly monoenergetic proton beam, dose de-
position per unit length on the proximal side of Bragg peak is defined by the proton stopping power and small 
contribution from secondary charged particles. While the shape of Bragg peak can vary depending on the hard-
ware configuration and beam properties in the treatment nozzle, the LET behavior is the same on the proximal 
side of the Bragg peak and is defined by the residual range of the proton beam. On the distal side of the Bragg 
peak, LET slope does depend on beam properties (SAD, energy spread, etc.). However, we found that linear in-
terpolation based on the LET slope calculated at the peak point of the Bragg peak gives reasonable approxima-
tion of the LET behavior on the distal side. Applying this approach to clinically measured Bragg peaks can give 
us dose averaged LET values at each point of the depth dose curve. 
In our calculations of RBE-weighted dose, we rely on the phenomenological model proposed by Wilkens and 
Olfke [22] linking proton RBE with dose averaged LET values. Other RBE models exists that instead of simple 
linear relationship between proton and x-ray radio sensitivity parameters (α, β) assume stronger tissue depen-
dence of RBE on α/β ratio, see Carabe et al. [40]. However, we feel that current experimental data do not war-
rant any proton RBE correlation with α/β ratio. This lack of correlation was also reported by Paganetti et al. [34]. 
In general, the phenomenological parameterization of Wilkens and Olfke [22] may need to be further genera-
lized to wider sample of tissues but it gives the simplest way to link proton and x-ray therapies.  
Applying our LET and RBE calculation model to the typical treatment sites in proton therapy, we found that 
tissue dependence of RBE is negligible. This result matches well with ICRU-78 recommendation of using tis-
sue-independent mean RBE value of 1.1, which is based upon available in-vitro and in-vivo data. However, we 
suggest using caution since tissue-independence of proton RBE may not be applicable to all treatment sites and 
certainly may not be applicable to organs at risk adjacent to the treatment volume [15]. Instead, we suggest that 
a generic tissue-independent RBE-weighted set of Bragg peaks could be used to setup a machine configuration 
in treatment planning system for estimating RBE effects at typical treatment sites only. 
Using the RBE-weighted set of Bragg peaks measured at our center, we have computed RBE-weighted dose 
distributions in modulated proton beam delivery. In the middle of computed SOBPs the RBE-weighted dose was 
found in reasonable agreement with a generic RBE value of 1.1 as recommended [6]. However, the RBE values 
can be as large as 1.3 at the distal edge and as low as 1.05 near the proximal edge of SOBP dose distribution. 
Our calculations also suggest that there could be up to 10% difference between RBE values on distal corner of 
SOBP at different beam energies. Furthermore, RBE value on the proximal corner is influenced by both the 
beam energy and the value of SOBP modulation. Our findings are consistent with predictions of other models of 
calculating RBE-weighted dose [26]. 
Note that, the SOBP delivery implies superposition of Bragg peaks with different weighting factors. The 
Bragg peaks in the middle of SOBP deliver smaller dose than distal Bragg peaks to take into account dose al-
ready delivered by all those distal Bragg peaks. This may raise a concern about dose dependence of RBE. How-
ever, because of this “prior” dose from distal Bragg peaks and since the TOTAL physical dose within the SOBP 
is constant, we cannot apply dose effect to RBE weighted individual Bragg peaks comprising the SOBP. 
Our method also predicts higher RBE at the distal edge of the dose distribution, which can lead to an apparent 
extension of the physical range by about 1 mm in depth. Table 2 summarizes the calculated RBE values and 
range extensions for the SOBP set. To compensate for elevated RBE at the distal end of SOBP, our calculations 
suggest reducing relative weight of the deepest Bragg peak and adding a negative slope of about 0.75%/cm to 
the physical dose within SOBP. The RBE-weighted dose calculations also suggest changes to common practice  
 
Table 2. RBE values at different locations of SOBPs and range extension.                                          
 
Range = 6 cm SOBP = 3.6 cm Range = 16 cm SOBP = 10 cm Range = 27 cm SOBP = 12 cm 
2 Gy 4 Gy 2 Gy 4 Gy 2 Gy 4 Gy 
RBE proximal 1.104 1.069 1.045 1.026 1.037 1.025 
RBE distal 1.334 1.223 1.253 1.166 1.247 1.164 
RBE average 1.17 1.113 1.101 1.063 1.088 1.058 
Range extension 1 mm 0.6 mm 1.3 mm 0.8 mm 1.4 mm 0.9 mm 
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of maximizing the weight of the deepest Bragg peak to sharpen the distal fall off in favor of optimizing relative 
weights of the Bragg peaks to smooth out distal gradient and to compensate for the RBE rise on the distal edge 
of SOBP. 
The analysis of hypo-fractionated proton dose delivery mode with 4 Gy per fraction indicates reduction of the 
biological effect in the SOBP region by about 7% compared with 2 Gy per fraction dose delivery mode as also 
noted by Carabe-Fernandez et al. [41]. Such calculations of the RBE-weighted dose could be used at the treat-
ment planning stage for estimating the effect of fractionation scheme on the expected outcome in proton radia-
tion therapy. 
5. Conclusions 
A computational model for estimating RBE-weighted dose based upon experimentally measured set of Bragg 
peaks is developed. The model allows one to calculate the dose averaged LET along the measured Bragg peak 
so that one can apply an LET to RBE conversion function. This routine can be applied to a set of Bragg peaks 
measured at any proton therapy facility. Combining the RBE-weighted pristine Bragg peaks according to the 
known weighting factors, one can obtain the RBE-weighted depth dose distribution in a modulated proton beam. 
The computed RBE-weighted absorbed dose exceeds physical dose by 5% - 30% over the SOBP region, de-
pending on SOBP modulation width, maximum beam energy and depth along the SOBP. 
The biological dose calculations strongly depend on the RBE versus LET relationship. However, we found 
that proton beam RBE tissue dependence is very small for four typical treatment sites. We also observed that the 
dose dependence of proton beam RBE has strongest effect mainly at the distal end of SOBP. The proposed me-
thod of computing the RBE-weighted dose in the proton beam may be useful in clinical practice for estimating 
the RBE-weighted dose delivered to the target and surrounding tissues, which could lead to treatment optimiza-
tion and better definitions of safety margins during the treatment planning. 
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